Acrivon Therapeutics (ACRV) Common Equity (2021 - 2026)
Acrivon Therapeutics (ACRV) recorded Common Equity of $86.67 million in Q2 2026, down 39.4% from $143.04 million a year earlier and down 9.3% from the prior quarter.
Powered by 
Analysis
Acrivon Therapeutics (ACRV) Common Equity (2021 - 2026) Analysis & Trends
At the end of FY2025, Acrivon Therapeutics reported Common Equity of $112.52 million, down 36.4% from FY2024.
- Across earlier years, Common Equity came in at $176.79 million in FY2024 (+45.9%), $121.2 million in FY2023 (-28.9%), $170.48 million in FY2022 and -$23.81 million in FY2021.
- The Q2 2026 figure is the lowest quarterly Common Equity since Q3 2022.
- On a year-over-year basis, Common Equity has declined for five consecutive quarters, with an average decline of 6.0% over the last eight quarters.
- Peak year-over-year performance for Common Equity in the last five years was growth of 48.5% in Q1 2025, against a decline of 40.4% in Q1 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at $95.52 million (Q1 2026), $112.52 million (Q4 2025) and $128.6 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Acrivon Therapeutics | 88.27 Mn | 88.27 Mn | - | 86.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 86.67 Mn |
| Mar 31, 2026 | 95.52 Mn |
| Dec 31, 2025 | 112.52 Mn |
| Sep 30, 2025 | 128.60 Mn |
| Jun 30, 2025 | 143.04 Mn |
| Mar 31, 2025 | 160.39 Mn |
| Dec 31, 2024 | 176.79 Mn |
| Sep 30, 2024 | 196.89 Mn |
| Jun 30, 2024 | 216.06 Mn |
| Mar 31, 2024 | 107.98 Mn |
| Dec 31, 2023 | 121.20 Mn |
| Sep 30, 2023 | 138.15 Mn |
| Jun 30, 2023 | 149.18 Mn |
| Mar 31, 2023 | 160.47 Mn |
| Dec 31, 2022 | 170.48 Mn |
| Sep 30, 2022 | -45.62 Mn |
| Jun 30, 2022 | -36.58 Mn |
| Mar 31, 2022 | -30.99 Mn |
| Dec 31, 2021 | -23.81 Mn |
| Sep 30, 2021 | -19.77 Mn |
API Access
Acrivon Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=ACRV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "ACRV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=ACRV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();